Virtual Investor is a leading platform providing investors with direct access to innovative companies, management teams and thought leaders.
Covered Companies
Covered Companies
Series
What This Means
Featuring Akari Therapeutics
November 11, 2026
Vatnak Vat-Ho, the Company’s newly appointed Chief Business Officer, discusses his background in oncology business development and strategic partnering, including experience with novel ADC payload technologies, and what attracted him to Akari. He highlights the potential of the Company’s PH1 payload, its differentiated dual mechanism of action and opportunities to advance its application across multiple ADC constructs.
What This Means
Featuring Daré Bioscience
October 28, 2026
Sabrina Martucci Johnson, President and CEO, shares her perspective on the recent White House Executive Order and how Daré Bioscience’s growing commercial portfolio and clinical pipeline position the Company to address critical unmet needs in women’s health.
What This Means
Featuring Ernexa Therapeutics
October 22, 2026
Sanjeev Luther, Ernexa President and Chief Executive Officer; Dr. Christopher Rohde, a member of Ernexa’s Scientific Advisory Board and developer of the technology underlying the Company’s platform; and Dr. Robert Pierce, Chief Scientific Officer, discuss three key areas central to Ernexa’s next phase of development: regulatory alignment, scientific differentiation and progress toward first-in-human clinical evaluation.
What This Means
Featuring Outlook Therapeutics
October 6, 2026
Kevin Lundquist, the Company’s Chief Financial Officer discusses the opportunity ahead as Outlook Therapeutics advances toward the commercial launch of LYTENAVA in the United States.
CEO CONNECT
Featuring Outlook Therapeutics
September 10, 2026
Bob Jahr, Chief Executive Officer of Outlook Therapeutics, discusses the potential of LYTENAVA to address the significant U.S. retina market by providing physicians with the only FDA-approved ophthalmic formulation of bevacizumab for wet AMD.
What This Means
September 01, 2026
Dylan Wenke, Chief Business Officer of CNS Pharmaceuticals, provides an update on its business development strategy as part of its broader transformation as the Company works to establish a pipeline focused on oncology or neurology with best in class potential.
CEO CONNECT
August 25, 2026
DARÉ President & CEO, Sabrina Martucci Johnson, discusses the Company’s shift to commercial stage, upcoming revenue opportunities, Ovaprene’s positive interim Phase 3 results and what could drive value over the next 12–18 months.
What This Means
July 22, 2026
Abizer Gaslightwala, Director, President and Chief Executive Officer of Akari Therapeutics discusses the significance of the Whitehawk collaboration and how it represents an important opportunity to evaluate Akari’s proprietary PH1 spliceosome modulating payload technology in combination with Whitehawk’s topoisomerase I inhibitor (TOP1i) ADC platform.
What This Means
July 15, 2026
Rob Berman, CEO discusses the Company’s recent news announcing the issuance of the first U.S. Patent covering the company’s enVVe® system, further expanding its intellectual property portfolio and laying the groundwork to dominate the large and untapped replacement venous valve market.
What This Means
Moleculin
July 06, 2026
Walter Klemp, Chairman and Chief Executive Officer of Moleculin discusses the positive preliminary unblinded efficacy results from the first 45 patients enrolled in Part A of the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML).
What This Means
June 25, 2026
Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses tthe upcoming launch of Flora Sync LF5™ and its significance as the company’s first consumer health product and opportunity to generate direct product revenue.
Past Events
Closing Bell Series
